# Loss of dystrophin reduces CB1 receptor expression and endocannabinoid-dependent synaptic plasticity in the cerebellar cortex.

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/dystrophin-endocannabinoid-system-cerebellar-cortex/
> **Published:** 2026-03-27T11:01:17-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T15:56:06-04:00
> **Clinical Summary:** Explore how dystrophin endocannabinoid system disruption reduces CB1 receptor expression and affects synaptic plasticity in the cerebellar cortex in DMD.

---

CED Clinical Relevance  #56Monitored Relevance  Early-stage or contextual signal requiring further evidence before action.
🔬 Evidence Watch  |  CED Clinic
Dmd[Endocannabinoid System](https://cedclinic.com/endocannabinoid-system-fear-extinction/)Cb1NeurologicalPreclinical

Journal
bioRxiv: the preprint server for biology

Study Type
[Clinical Study](https://cedclinic.com/cannabis-hyperemesis-syndrome-psychiatric-risk/)

Population
Human participants

Why This Matters

This preclinical research reveals a novel neurobiological mechanism linking dystrophin loss to [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) dysfunction in the cerebellum. Understanding CB1 receptor alterations in Duchenne Muscular Dystrophy could inform therapeutic approaches addressing the cognitive and neurological symptoms that accompany this devastating muscle disorder.

Clinical Summary
Researchers used immunofluorescent labeling and electrophysiology in dystrophin-deficient mouse models to examine CB1 receptor expression and endocannabinoid-mediated synaptic plasticity in cerebellar cortex. The study found reduced CB1 receptor expression and impaired endocannabinoid-dependent plasticity at inhibitory synapses when dystrophin was absent. This represents the first direct investigation of how dystrophin loss affects central nervous system endocannabinoid signaling, potentially explaining some neurological manifestations in DMD patients. As a preprint study using animal models, these findings require peer review and human validation.

Dr. Caplan’s Take

“This mechanistic research opens an intriguing therapeutic window, but we’re several steps away from clinical application. The endocannabinoid system’s role in DMD neurological symptoms remains largely unexplored in human patients.”

Clinical Perspective
🧠 Clinicians treating DMD patients should note this emerging evidence of endocannabinoid system involvement in disease pathophysiology. While premature for immediate therapeutic decisions, this research suggests future cannabis-based interventions might address neurological symptoms beyond the well-established muscle-related benefits currently being investigated in DMD.

💬 Join the Conversation

Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan)

Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/)

Have thoughts on this? Share it:

[𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Loss%20of%20dystrophin%20reduces%20CB1%20receptor%20expression%20and%20endocannabinoid-dependent...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41890000/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41890000/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Loss%20of%20dystrophin%20reduces%20CB1%20receptor%20expression%20and%20endocannabinoid-dependent...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41890000/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/)

📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41890000/](https://pubmed.ncbi.nlm.nih.gov/41890000/)

Table of Contents

- [FAQ](#FAQ)[How did researchers study dystrophin loss and the endocannabinoid system?](#How_did_researchers_study_dystrophin_loss_and_the_endocannabinoid_system)
- [What happened to CB1 receptors when dystrophin was missing?](#What_happened_to_CB1_receptors_when_dystrophin_was_missing)
- [Why could these findings matter for people with Duchenne muscular dystrophy?](#Why_could_these_findings_matter_for_people_with_Duchenne_muscular_dystrophy)
- [Can these results guide treatment for DMD patients now?](#Can_these_results_guide_treatment_for_DMD_patients_now)
- [Related](#Related)

## FAQ

### How did researchers study dystrophin loss and the endocannabinoid system?

They studied dystrophin-deficient mouse models, using immunofluorescent labeling and electrophysiology to examine CB1 receptor expression and endocannabinoid-mediated synaptic plasticity in the cerebellar cortex. Dystrophin is missing in Duchenne Muscular Dystrophy (DMD). The work was posted as a preprint on bioRxiv and still requires peer review.

### What happened to CB1 receptors when dystrophin was missing?

CB1 receptor expression was reduced in the cerebellar cortex of the dystrophin-deficient mice. The researchers also found impaired endocannabinoid-dependent synaptic plasticity at inhibitory synapses when dystrophin was absent, suggesting that dystrophin loss disrupts endocannabinoid signaling in this part of the brain.

### Why could these findings matter for people with Duchenne muscular dystrophy?

The study is described as the first direct investigation of how dystrophin loss affects endocannabinoid signaling in the central nervous system. Its findings could potentially help explain some neurological manifestations seen in DMD patients. However, the work used mouse models and still requires peer review and human validation, and the endocannabinoid system’s role in DMD neurological symptoms remains largely unexplored in human patients.

### Can these results guide treatment for DMD patients now?

No. This is a preprint study in mouse models, so the findings still require peer review and validation in humans before they could inform treatment decisions. The work points to a possible mechanism involving CB1 receptors in the cerebellum, but it did not test any cannabinoid treatment.

{“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “Loss of dystrophin reduces CB1 receptor expression and endocannabinoid-dependent synaptic plasticity in the cerebellar cortex.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41890000/”, “about”: “biorxiv preprint server biology clinical study”, “isPartOf”: “bioRxiv: the preprint server for biology”}

 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 

Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance

 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Medical Consulting](https://cedclinic.com/book/)
 [Cannabis Care](https://cedclinic.com/book/)
 

 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 

RELATED READING AT CED CLINIC

Continue exploring the evidence

[Cannabis Use Disorder Treatment Europe Review](https://cedclinic.com/cannabis-use-disorder-treatment-europe-evidence-watch/)

A comprehensive review of [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) treatments in Europe, highlighting clinical evidence and therapeutic approaches.

[Read the Review](https://cedclinic.com/cannabis-use-disorder-treatment-europe-evidence-watch/)

[The effect of cannabis use on the time course of positive and negative affect in the daily life of youth.](https://cedclinic.com/cannabis-effects-youth-daily-mood-patterns/)

Study exploring how [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) influences emotional states over time in young individuals, with implications for mental health.

[Explore the Study](https://cedclinic.com/cannabis-effects-youth-daily-mood-patterns/)

[Substance Use and Suicide Attempts in Adolescents: A Comparative Analysis of Clinical and Psychosocial Risk Factors.](https://cedclinic.com/adolescent-substance-use-suicide-risk-analysis/)

An analysis of the relationship between [substance use](https://cedclinic.com/stroke-risk-assessment-substance-use/) and suicide attempts among adolescents, focusing on clinical and psychosocial risks.

[Learn More](https://cedclinic.com/adolescent-substance-use-suicide-risk-analysis/)

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).